CytomX Therapeutics Inc. (NASDAQ:CTMX) finished Friday with an addition of $0.03 to close at $1.60, an upside of 1.91 percent. An average of 640,340 shares of common stock have been traded in the last five days. There was a gain of $0.0700 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 762,130 shares traded, while the 50-day average volume stands at 1,641,270.
CTMX stock has decreased by -8.05% in the last month. The company shares reached their 1-month lowest point of $1.3300 on 12/09/22. With the stock rallying to its 52-week high on 02/09/22, shares of the company touched a low of $1.17 and a high of $4.73 in 52 weeks. It has reached a new high 4 times so far this year and lost -63.05% or -$2.7300 in price. In spite of this, the price is down -66.17% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
CTMX stock investors should be aware that CytomX Therapeutics Inc. (CTMX) stock had its last reported insider trading activity 164 days ago on Jul 20. In this transaction, the insider spent $10,612. Chief Business Officer, Landau Jeffrey B, disposed of 4,206 shares at a price of $1.42 on Jul 20. The insider now owns more than $5,982 worth of shares. Prior to that, General Counsel ROWLAND LLOYD A went on to Sale 5,602 shares at $1.42 each on Jul 20. An amount of $7,968 was transacted.
CytomX Therapeutics Inc. (CTMX) stock’s beta is 0.49. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1.45, the price-to-book (PB) ratio at 3.72.
The quick ratio of CytomX Therapeutics Inc. for the three months ended June 29 was 2.00, and the current ratio was 2.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $153.35 million compared to revenue of $69.57 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, CytomX Therapeutics Inc.’s return on assets was -34.80%.
For the three-month period that ended June 29, CytomX Therapeutics Inc. had $99.25 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$23.3 million in the quarter, while revenues of -$24.18 million were grew 3.09%. The analyst consensus anticipated CytomX Therapeutics Inc.’s latest quarter earnings to come in at -$0.36 per share, but it turned out to be -$0.37, a -2.80% surprise. For the quarter, EBITDA amounted to -$23.33 million. Shareholders own equity worth $66.08 million.
From a technical analysis perspective, let’s take a brief look at CytomX Therapeutics Inc. (CTMX) price momentum. RSI 9-day as of the close on 30 December was 55.52%, suggesting the stock is Neutral, with historical volatility in this time frame at 79.05%.
As of today, CTMX’s price is $1.5420 +4.58% or $0.0700 from its 5-day moving average. However, the stock’s current price level is +20.30% above the SMA50 and -46.67% below the SMA200.
The stochastic %K and %D were 66.61% and 57.62%, respectively, and the average true range (ATR) was 0.0989. With the 14-day stochastic at 69.39% and the average true range at 0.1022, the RSI (14) stands at 53.62%. The stock has reached 0.0389 on the 9-day MACD Oscillator while the 14-day reading was at 0.0164.
BMO Capital Markets downgraded CytomX Therapeutics Inc. (NASDAQ: CTMX) to a a Market perform rating in its most recent analyst report. Previously, the stock was rated as an Outperform. The consensus rating for CytomX Therapeutics Inc. (CTMX) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell CTMX, while 7 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 0 others rate it as a “buy”.
What is CTMX’s price target for the next 12 months?
Analysts predict a range of price targets between $1.31 and $4.00, with a median target of $2.30. Taking a look at these predictions, the average price target given by analysts for CytomX Therapeutics Inc. (CTMX) stock is $2.53.